FDA Approves Elranatamab for Multiple Myeloma FDA Approves Elranatamab for Multiple Myeloma

Elranatamab is an off-the-shelf, B-cell maturation antigen CD3-targeted bispecific antibody.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news